Literature DB >> 33211556

Correlation of Retinal Thickness and Swept-Source Optical Coherence Tomography Angiography Derived Vascular Changes in Patients with Neovascular Age-Related Macular Degeneration.

R Told1, G S Reiter1, M Schranz1, A Reumueller1, V Hacker1, T J Mittermueller1, P K Roberts1, S Sacu1, U Schmidt-Erfurth1.   

Abstract

Purpose: The aim of this study was to investigate whether structural OCT changes, in specific retinal thickness, is associated with the vascular response within the nAMD CNV lesion. In other words, whether SSOCTA derived parameters may prove suitable to assess CNV activity in future.
Methods: During the first 3 months patients were prospectively followed with visits at days 7, and 14 after each anti-VEGF treatment up to day 90. At baseline, day 30 and 60 Aflibercept was administered. OCT-derrived retinal thickness (RT) and OCTA-derived CNV lesion parameters (vessel area [VA]), total vessel length [TVL], total number of junctions [TNJ], junction density [JD]) were determined. Parameters were exported from SSOCT/A (PlexElite, Zeiss) images using the semi-automated AngioTool software. Additionally, the superficial and deep vascular plexus fractal dimension of the para- and perifoveal region were identified. Consequently, all OCTA derived parameters were correlated with RT.
Results: 16 consecutive patients presenting with treatment-naïve, SSOCTA-positive CNV lesions were included. A weak to moderate statistically significant correlation was found between the mean RT of the inner as well as the outer ETDRS ring with the SSOCTA-derived vascular markers vessel area (VA; r2 = -0.38, p < .001; r2 = -0.47, p < .001, respectively), total vessel length, (TVL; r2 = -0.38, p < .001; r2 = -0.48, p < .001, respectively) and total number of junctions (TNJ; r2 = -0.35, p < .001; r2 = -0.44, p < .001, respectively). Junctions density (JD), and all variables based on fractal dimension (FD) did not show statistically significant correlations with retinal thickness measurements.Conclusions: In summary, we could confirm a moderate, however, statistically significant correlation between mean para- and perifoveal retinal thickness and the SSOCTA derived vascular parameters VA, TVL, and TNJ. This leads us to the conclusion that an SSOCTA-based activity analysis of the CNV complex is not yet a substitute for retinal thickness or in-depth fluid analysis in patients with nAMD.

Entities:  

Keywords:  Biomarker; CNV; SSOCT; SSOCTA; nAMD

Mesh:

Substances:

Year:  2021        PMID: 33211556     DOI: 10.1080/02713683.2020.1849734

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  4 in total

1.  Correlation of retinal alterations with vascular structure of macular neovascularisation in swept-source optical coherence tomography angiography in age-related macular degeneration.

Authors:  Henrik Faatz; Kai Rothaus; Martin Ziegler; Marius Book; Georg Spital; Britta Heimes-Bussmann; Daniel Pauleikhoff; Albrecht Lommatzsch
Journal:  Int Ophthalmol       Date:  2022-01-13       Impact factor: 2.029

2.  Characterization of the Canine Retinal Vasculature With Optical Coherence Tomography Angiography: Comparisons With Histology and Fluorescein Angiography.

Authors:  Ana Ripolles-Garcia; Gordon Ruthel; Gui-Shuang Ying; Yineng Chen; Nicolas Cuenca; Gustavo D Aguirre; William A Beltran
Journal:  Front Neuroanat       Date:  2021-12-13       Impact factor: 3.543

3.  Utilization of deep learning to quantify fluid volume of neovascular age-related macular degeneration patients based on swept-source OCT imaging: The ONTARIO study.

Authors:  Simrat K Sodhi; Austin Pereira; Jonathan D Oakley; John Golding; Carmelina Trimboli; Daniel B Russakoff; Netan Choudhry
Journal:  PLoS One       Date:  2022-02-14       Impact factor: 3.240

4.  1-Year Fixed-Regimen Bevacizumab Treatment in DME-Vascular Network Image Analysis in Optical Coherence Tomography Angiography Study.

Authors:  Magdalena Hunt; Adam Wylęgała; Edward Wylęgała; Sławomir Teper
Journal:  J Clin Med       Date:  2022-04-11       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.